Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 1/2005

01-01-2005 | Concise Article

Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy

Authors: M. W. R. Pletz, L. McGee, O. Burkhardt, H. Lode, K. P. Klugman

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2005

Login to get access

Abstract

Reported here is the case of a patient with underlying chronic obstructive pulmonary disease (COPD) in whom ciprofloxacin treatment of a lower respiratory tract infection failed subsequent to ciprofloxacin treatment of an exacerbation of COPD several weeks earlier. During the second course of ciprofloxacin therapy, the patient’s condition continued to deteriorate, and she was admitted to the intensive care unit. Bilateral pneumonia was diagnosed. Streptococcus pneumoniae, serotype 11A, resistant to ciprofloxacin was isolated from the sputum. Sequencing revealed a S79F mutation in parC and there was evidence of an efflux pump. The patient improved rapidly after administration of azithromycin and ampicillin/sulbactam. This report of treatment failure due to ciprofloxacin-resistant Streptococcus pneumoniae shows that fluoroquinolones should be avoided when treating patients who have recently received this class of antibiotics.
Literature
1.
go back to reference Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433CrossRefPubMed Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433CrossRefPubMed
2.
go back to reference Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P et al (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750CrossRefPubMed Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P et al (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750CrossRefPubMed
3.
go back to reference Hutchinson J (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 347:65–67; author reply 65–67CrossRef Hutchinson J (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 347:65–67; author reply 65–67CrossRef
4.
go back to reference Kays MB, Smith DW, Wack ME, Denys GA (2002) Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22:395–399CrossRefPubMed Kays MB, Smith DW, Wack ME, Denys GA (2002) Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22:395–399CrossRefPubMed
5.
go back to reference Gertz RE Jr, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA et al (2003) Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 41:4194–4216CrossRefPubMed Gertz RE Jr, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA et al (2003) Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 41:4194–4216CrossRefPubMed
6.
go back to reference National Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA7 National Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA7
7.
go back to reference Fukuda H, Hiramatsu K (1999) Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:410–412PubMed Fukuda H, Hiramatsu K (1999) Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:410–412PubMed
8.
go back to reference Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A (2003) Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Resist 9:17–24CrossRefPubMed Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A (2003) Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Resist 9:17–24CrossRefPubMed
9.
go back to reference Lim S, Bast D, McGeer A, de Azavedo J, Low DE (2003) Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 9:833–837PubMed Lim S, Bast D, McGeer A, de Azavedo J, Low DE (2003) Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 9:833–837PubMed
10.
go back to reference Croisier D, Etienne M, Bergoin E, Charles PE, Lequeu C, Piroth L et al (2004) Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 48:1699–1707CrossRefPubMed Croisier D, Etienne M, Bergoin E, Charles PE, Lequeu C, Piroth L et al (2004) Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 48:1699–1707CrossRefPubMed
11.
go back to reference Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE (2003) Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 37:376–381CrossRefPubMed Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE (2003) Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 37:376–381CrossRefPubMed
Metadata
Title
Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy
Authors
M. W. R. Pletz
L. McGee
O. Burkhardt
H. Lode
K. P. Klugman
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-004-1254-x

Other articles of this Issue 1/2005

European Journal of Clinical Microbiology & Infectious Diseases 1/2005 Go to the issue

Announcements

Announcements

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine